There are currently 621 clinical trials in Sacramento, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California Davis Comprehensive Cancer Center, University of California, Davis Medical Center, University of California, Davis and Sutter Medical Center Sacramento. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Oral Supplementation of Astaxanthin on Skin Photoaging, Hydration and Elasticity
NCT05882084
Recruiting
This study is a double-blind placebo controlled study to assess whether oral astaxanthin can improve skin hydration, skin elasticity, improve skin pigmentation, and reduce facial redness.
Gender:
Female
Ages:
Between 30 years and 55 years
Trial Updated:
07/24/2023
Locations: Integrative Skin Science and Research, Sacramento, California
Conditions: Photoaging
Register for Updates
Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in Schizophrenia
NCT04267003
Recruiting
People with schizophrenia often have problems with attention, learning and memory and other cognitive abilities that interfere with their work and school performance. Unfortunately, even our best treatments often do not significantly reduce these cognitive problems. The current study investigates whether or not delivering a very small electrical current to people's foreheads (called, transcranial direct current stimulation; (tDCS)) might improve functioning in the front part of the brain and red... Read More
Gender:
All
Ages:
Between 18 years and 47 years
Trial Updated:
07/21/2023
Locations: Imaging Research Center, Sacramento, California
Conditions: Schizophrenia
Register for Updates
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
NCT05219110
Recruiting
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).
Gender:
All
Ages:
Between 9 months and 21 years
Trial Updated:
07/21/2023
Locations: University of California, Davis, Sacramento, California
Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Register for Updates
Ureteral Stent Placement After Ureteroscopy for Renal Stones: A Randomized Controlled Trial
NCT03855787
Recruiting
The rationale for this study is to determine if there is a difference in complications among patients undergoing ureteroscopy for renal stones who receive a stent compared to not receiving a stent postoperatively.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/20/2023
Locations: University of California Davis, Sacramento, California
Conditions: Kidney Calculi
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: UC Davis, Sacramento, California
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT03808922
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
All
Ages:
All
Trial Updated:
07/19/2023
Locations: University of California Davis Health System, Sacramento, California
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Register for Updates
Shaping Tolerance for Delayed Rewards
NCT03457402
Recruiting
Deficits in self-control are of major public health relevance as they contribute to several negative outcomes for both individuals and society. For children, developing self-control is a critically important step toward success in academic settings and social relationships, yet there are few non-pharmacological approaches that have been successful in increasing self-control. We found in our earlier studies that self-control can be increased in preschool-aged children with high impulsivity by usi... Read More
Gender:
All
Ages:
Between 3 years and 6 years
Trial Updated:
07/10/2023
Locations: UC Davis MIND Institute, Sacramento, California
Conditions: Impulsivity
Register for Updates
Fidgeting and Attentional and Emotional Regulation in ADHD
NCT04526600
Recruiting
This project will study how fidgeting relates to cognitive and emotional functioning in adults with attention-deficit/hyperactivity disorder (ADHD). It will determine, in a laboratory setting, whether movement and access to a "fidget device" providing sensory and motor stimulation can improve cognitive and emotional regulation (including on physiological measures) in adult ADHD. The investigators will also acquire pilot data for machine learning analyses to be used in future, large scale studies... Read More
Gender:
All
Ages:
Between 18 years and 30 years
Trial Updated:
07/10/2023
Locations: UC Davis MIND Institute, Sacramento, California
Conditions: ADHD
Register for Updates
Optimal Treatment for Recurrent Clostridium Difficile
NCT02667418
Recruiting
The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile infection.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/07/2023
Locations: VA Northern California Health Care System, Mather, CA, Sacramento, California
Conditions: Clostridium, Difficile, Fidaxomicin, Vancomycin
Register for Updates
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
NCT04166877
Recruiting
Magnesium is a naturally occurring mineral that is important for your body and brain. Magnesium sulfate (study drug) is a medication containing magnesium that is commonly used to improve low blood levels of magnesium. Magnesium sulfate has also proven to be successful in managing pain before and after surgery. However, this drug has primarily been used for pain control in patients undergoing surgery. Patients in the ICU with injuries also need good pain control. Using magnesium may assist in dec... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/07/2023
Locations: UC Davis Health, Sacramento, California
Conditions: Trauma, Acute Pain
Register for Updates
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
NCT05843448
Recruiting
This phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer. IO102-IO103 is a novel IDO and PD-L1 peptide based immune-modulatory therapeutic. It is designed to activate the patient's own immune cells (called T-cells) to fight the tumor and stop the tumor cells escaping from the body's immune system. IO102-IO103 works to directly kill tumor cells and remove the bod... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/06/2023
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Register for Updates
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
NCT05349643
Recruiting
AMB-051-07 is an Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension which will enroll approximately 48 adult subjects with TGCT for IA doses over a 24-week dosing period (Part 1) with a Part 2 OLE of 6 treatment and/or observational cycles of 12 weeks each followed by 12 weeks of follow-up.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/05/2023
Locations: AmMax Bio, Clinical Site, Sacramento, California
Conditions: Pigmented Villonodular Synovitis, TGCT, Tenosynovial Giant Cell Tumor
Register for Updates